U31402-A-U201 - Virginia Cancer Specialists

Trial ID U31402-A-U201

Sponsor ID HERTHENA-Lung01

A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Principal Investigator

Alexander I. Spira, MD, PhD, FACP

1 Location

Lung

Locations

Fairfax Office

Learn More About This Trial

Name*
First Last
Diagnosis / Trial Interested In*
Email*
Enter Email Confirm Email
Comments
Phone
CAPTCHA

Other Relevant Trials

Trial ID NAV-1104

Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

Principal Investigator

Alexander I. Spira, MD, PhD, FACP

1 Location

Lung

Trial ID FURMO

Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations